세계의 철 결핍증 주사제 시장 보고서(2025년)
Iron Deficiency Injectable Global Market Report 2025
상품코드 : 1825429
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ₩ 6,482,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ₩ 9,370,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ₩ 12,257,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

철 결핍증 주사제 시장의 규모는 향후 수년간 급성장할 것으로 전망됩니다. 2029년에는 CAGR 10.6%로 228억 1,000만 달러로 성장할 전망입니다. 예측기간의 성장은 노인 인구 증가, 세계적인 건강에 대한 노력, 정부의 이니셔티브, 만성질환에 대한 치료 증가, 급속한 철분 보급 등에 기인할 것으로 전망됩니다. 예측기간의 주요 동향으로는 철분제제의 진보, 디지털 건강 솔루션, 철 결핍증 주사제 요법의 진보, 철 기반 약물의 채용 등이 있습니다.

향후 5년간의 예측 성장률 10.6%는 과거 예측에서 0.1% 소폭 감소한 수치입니다. 이러한 성장세 둔화는 주로 미국과 다른 국가 간의 관세의 영향 때문입니다. 관세의 부과는 스위스와 오스트리아에서 조달하는 정맥 주사용 철분제제의 비용을 증가시키고, 중증 빈혈의 치료가 손상되거나, 수액 센터의 운영 비용이 상승할 수 있기 때문에 미국의 건강 관리 시스템에 중대한 과제를 초래할 수 있습니다. 또한 상호관세나 무역 마찰 및 제한의 격화에 의한 세계 경제 및 무역에 대한 악영향에 의해 그 영향은 보다 광범위하게 미칠 것으로 보입니다.

철 결핍증 주사제 시장은 다낭성 난소 증후군(PCOS)의 유병률 증가로 성장할 것으로 예측됩니다. PCOS는 일반적으로 발생하는 호르몬 장애이며 주로 생식 연령의 여성의 난소에 영향을 미칩니다. PCOS는 종종 철분 과다증을 일으키고 월경 출혈 과다증과 빈혈을 야기합니다. 주사용 철 결핍증 치료제는 이 병태를 다루는 효과적인 솔루션을 제공합니다. 예를 들어 미국에 본부를 둔 보건전문기관 세계보건기구(WHO)는 2023년 6월 PCOS는 세계적으로 생식 연령에 있는 여성의 약 8-13%가 병을 앓고 있으며, 그 70%는 진단되지 않았다고 추정했습니다. 따라서 다낭성 난소 증후군(PCOS)의 유병률 증가는 철 결핍증 주사제 시장 성장의 원동력이 되고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

CSM
영문 목차

영문목차

Iron deficiency refers to a condition where the body lacks adequate iron, leading to decreased production of red blood cells and hemoglobin. Iron deficiency injectables refer to injectable medications or solutions used to treat iron deficiency. These injectable forms of iron allow for direct delivery of the iron into the bloodstream, bypassing the digestive system.

The main types of iron deficiency injectables are iron dextran, iron sucrose and ferric carboxymaltose. Iron dextran is a complex of iron and a carbohydrate called dextran. The various types of branded or generics are branded, generics that are used in various applications such as chronic kidney disease, inflammatory bowel disease, cancer and others and also by various end users such as hospitals, homecare, specialty clinics and others.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The iron deficiency injectables market research report is one of a series of new reports from The Business Research Company that provides iron deficiency injectables market statistics, including iron deficiency injectables industry global market size, regional shares, competitors with an iron deficiency injectables market share, detailed iron deficiency injectables market segments, market trends and opportunities and any further data you may need to thrive in the iron deficiency injectables industry. This iron deficiency injectables market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The iron deficiency injectable market size has grown strongly in recent years. It will grow from $14.06 billion in 2024 to $15.22 billion in 2025 at a compound annual growth rate (CAGR) of 8.3%. The growth in the historic period can be attributed to high prevalence of iron deficiency anemia treatments, bariatric surgery patients, pediatric and adolescent patients, growing pregnancy.

The iron deficiency injectable market size is expected to see rapid growth in the next few years. It will grow to $22.81 billion in 2029 at a compound annual growth rate (CAGR) of 10.6%. The growth in the forecast period can be attributed to geriatric population, global health initiatives, government initiatives, incresing treatments for chronic conditions, rapid iron replenishment. Major trends in the forecast period include advances in iron formulations, digital health solutions, advancements in iron deficiency injectable therapy, adoption of iron-based drugs.

The forecast of 10.6% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. The imposition of tariffs may pose a significant challenge for U.S. healthcare by increasing costs for intravenous iron formulations sourced from Switzerland and Austria, potentially compromising treatment for severe anemia and raising infusion center operational costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The iron deficiency injectables market is anticipated to experience growth due to the increasing prevalence of polycystic ovary syndrome (PCOS). PCOS is a commonly occurring hormonal disorder that predominantly affects individuals with ovaries, primarily women in their reproductive years. PCOS often leads to iron overload, resulting in excessive menstrual bleeding and subsequent anemia in affected patients. Injectable iron deficiency medications offer an effective solution to address this condition. For example, as of June 2023, the World Health Organization, a specialized health agency based in the United States, estimates that PCOS affects approximately 8-13% of reproductive-aged women globally, with 70% of cases remaining undiagnosed. Hence, the rising prevalence of polycystic ovary syndrome (PCOS) serves as a driving force behind the growth of the iron deficiency injectables market.

The substantial prevalence of malnutrition is a key driver behind the expansion of the iron deficiency injectable market. Malnutrition signifies a health condition marked by an imbalance between the intake of essential nutrients and the nutritional requirements of the body. Iron deficiency injectables play a crucial role in addressing malnutrition by swiftly replenishing iron stores and delivering a concentrated dose of iron that is readily absorbed into the bloodstream, enabling the rapid correction of the deficiency. For example, in March 2023, the California Department of Public Health reported an increase in malnutrition-related deaths to 1,406 in 2022, marking a notable 22.36% surge compared to the 1,149 deaths recorded in 2021. As a result, the heightened prevalence of malnutrition is expected to drive the future growth of the iron deficiency injectable market.

Prominent companies operating in the iron deficiency injectables market are actively engaged in the development of innovative therapies, such as INJECTAFER, to maintain their competitive standing in the market. For instance, in June 2023, Daiichi Sankyo Company, a U.S.-based healthcare company, in collaboration with American Regent Inc., a U.S.-based injectables manufacturer, introduced INJECTAFER (ferric carboxymaltose injection) for the treatment of iron deficiency. This innovative therapy received approval from the Food and Drug Administration (FDA), a U.S. government agency. INJECTAFER is recognized as the first and only intravenous iron replacement therapy approved for adult patients with chronic and progressive heart failure. It has undergone rigorous evaluation through more than 40 clinical trials involving over 8,800 participants from various countries, demonstrating its effectiveness in patients, including adults and pediatric individuals with iron-deficient anemia and heart failure.

In August 2022, CSL Limited, an Australian-based biotechnology company specializing in the production of iron deficiency injectables, completed the acquisition of Vifor Pharma for an undisclosed sum. This strategic acquisition reinforces CSL's commitment to patient care and enhances its capability to provide advanced medications. Vifor Pharma, headquartered in Switzerland, is a pharmaceutical company renowned for its offerings in the field of iron deficiency injectables.

Major companies operating in the iron deficiency injectable market are Daiichi Sankyo Company Limited, Pfizer Inc., Aetna Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A, AstraZeneca PLC, GSK PLC, Fresenius Medical Care, Teva Pharmaceutical Industries Ltd., Mylan N.V., B Braun Medical Inc., Sandoz, Fresenius Kabi AG, Cipla Limited, Emcure Pharmaceuticals Ltd., AMAG Pharmaceuticals Inc., Luitpold Pharmaceuticals Inc., Akebia Therapeutics Inc., Covis Pharma GmbH, Keryx Biopharmaceuticals Inc., Rockwell Medical Inc., American Regent Inc., Galen Medical Group.

North America was the largest region in the iron deficiency injectable market in 2024. The regions covered in iron deficiency injectable report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the iron deficiency injectable market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The iron deficiency injectable market consists of sales of ferumoxide, sodium ferric gluconate and iron gluconate. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Iron Deficiency Injectable Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on iron deficiency injectable market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for iron deficiency injectable ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The iron deficiency injectable market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Iron Deficiency Injectable Market Characteristics

3. Iron Deficiency Injectable Market Trends And Strategies

4. Iron Deficiency Injectable Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Iron Deficiency Injectable Growth Analysis And Strategic Analysis Framework

6. Iron Deficiency Injectable Market Segmentation

7. Iron Deficiency Injectable Market Regional And Country Analysis

8. Asia-Pacific Iron Deficiency Injectable Market

9. China Iron Deficiency Injectable Market

10. India Iron Deficiency Injectable Market

11. Japan Iron Deficiency Injectable Market

12. Australia Iron Deficiency Injectable Market

13. Indonesia Iron Deficiency Injectable Market

14. South Korea Iron Deficiency Injectable Market

15. Western Europe Iron Deficiency Injectable Market

16. UK Iron Deficiency Injectable Market

17. Germany Iron Deficiency Injectable Market

18. France Iron Deficiency Injectable Market

19. Italy Iron Deficiency Injectable Market

20. Spain Iron Deficiency Injectable Market

21. Eastern Europe Iron Deficiency Injectable Market

22. Russia Iron Deficiency Injectable Market

23. North America Iron Deficiency Injectable Market

24. USA Iron Deficiency Injectable Market

25. Canada Iron Deficiency Injectable Market

26. South America Iron Deficiency Injectable Market

27. Brazil Iron Deficiency Injectable Market

28. Middle East Iron Deficiency Injectable Market

29. Africa Iron Deficiency Injectable Market

30. Iron Deficiency Injectable Market Competitive Landscape And Company Profiles

31. Iron Deficiency Injectable Market Other Major And Innovative Companies

32. Global Iron Deficiency Injectable Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Iron Deficiency Injectable Market

34. Recent Developments In The Iron Deficiency Injectable Market

35. Iron Deficiency Injectable Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기